During the last session, Forte Biosciences Inc (NASDAQ:FBRX)’s traded shares were 0.38 million, with the beta value of the company hitting 0.50. At the end of the trading day, the stock’s price was $16.00, reflecting an intraday gain of 2.30% or $0.36. The 52-week high for the FBRX share is $21.25, that puts it down -32.81 from that peak though still a striking 74.31% gain since the share price plummeted to a 52-week low of $4.11. The company’s market capitalization is $23.39M, and the average intraday trading volume over the past 10 days was 3.1 million shares, and the average trade volume was 486.68K shares over the past three months.
Forte Biosciences Inc (FBRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. FBRX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.74.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Forte Biosciences Inc (NASDAQ:FBRX) trade information
Forte Biosciences Inc (FBRX) registered a 2.30% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.30% in intraday trading to $16.00, hitting a weekly high. The stock’s 5-day price performance is 173.97%, and it has moved by 245.57% in 30 days. Based on these gigs, the overall price performance for the year is 48.84%. The short interest in Forte Biosciences Inc (NASDAQ:FBRX) is 982.0 shares and it means that shorts have 0.09 day(s) to cover.
Forte Biosciences Inc (FBRX) estimates and forecasts
Statistics show that Forte Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Forte Biosciences Inc (FBRX) shares have gone up 10.36% during the last six months, with a year-to-date growth rate more than the industry average at 61.08% against 17.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 51.36%. While earnings are projected to return 35.51% in 2024.
FBRX Dividends
Forte Biosciences Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Forte Biosciences Inc (NASDAQ:FBRX)’s Major holders
Forte Biosciences Inc insiders own 10.94% of total outstanding shares while institutional holders control 54.05%, with the float percentage being 60.69%. TYBOURNE CAPITAL MANAGEMENT (HK) LTD is the largest shareholder of the company, while 27.0 institutions own stock in it. As of 2024-06-30, the company held over 3.62 million shares (or 7.8653% of all shares), a total value of $1.95 million in shares.
The next largest institutional holding, with 3.27 million shares, is of PERCEPTIVE ADVISORS LLC’s that is approximately 7.0858% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.75 million.
Also, the Mutual Funds coming in first place with the largest holdings of Forte Biosciences Inc (FBRX) shares are Alger Health Sciences Fund and Vanguard Total Stock Market Index Fund . Data provided on Jul 31, 2024 indicates that Alger Health Sciences Fund owns about 47.71 shares. This amounts to just over 3.26 percent of the company’s overall shares, with a $0.76 million market value. The same data shows that the other fund manager holds slightly less at 19.5, or about 1.33% of the stock, which is worth about $0.31 million.
